文献速递甲状腺疾病

CDKN2C拷贝数在散发性甲状腺髓样癌中的作用

Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2016-10-18

该研究在单中心62例散发性甲状腺髓样癌患者中评估体细胞RETM918T突变与CDKN2C拷贝数缺失的关联。CDKN2C缺失与更差的M分期和AJCC总分期相关,且与总生存期缩短相关,合并RETM918T突变时关系更强。

要点

  • CDKN2C缺失与散发性甲状腺髓样癌更差的M分期和AJCC总分期相关。
  • CDKN2C缺失患者中位总生存4.14年 vs 无缺失者18.27年(p<0.0001)。
  • 合并RETM918T突变与CDKN2C缺失者中位总生存最短,为2.38年。

核心结论

  • 体细胞CDKN2C缺失与散发性甲状腺髓样癌初诊时远处转移及总生存期下降相关,合并RETM918T突变时该关系增强。

研究设计与样本

  • 单中心回顾性队列研究,纳入1983年至2009年初次手术的62例散发性甲状腺髓样癌患者,评估体细胞RETM918T突变和CDKN2C拷贝数缺失。

主要发现

  • 62例中男性36例(58%),初次手术中位年龄53岁(范围22-81岁),中位肿瘤大小30 mm(范围6-145 mm),29例(57%)存在甲状腺外侵犯。
  • 初诊时淋巴结和/或远处转移分别为47/60例(78%)和12/61例(20%)。
  • 删失观察的中位随访时间为10.5年(范围1.1-27.8年)。
  • CDKN2C缺失患者与无缺失患者的中位总生存分别为4.14年(CI 1.93-NA) vs 18.27年(CI 17.24-NA),p<0.0001。
  • 合并体细胞RETM918T突变与CDKN2C缺失、无体细胞RETM918T突变与CDKN2C缺失、体细胞RETM918T突变与CDKN2C 2N、无体细胞RETM918T突变与CDKN2C 2N四组的中位总生存分别为2.38年(CI 1.67-NA)、10.81年(CI 2.46-NA)、17.24年(CI 9.82-NA)、未达到(CI 13.46-NA),p<0.0001。

临床怎么用

  • 作者认为,进一步明确参与转移性甲状腺髓样癌进展的基因将是识别疾病进展通路和新治疗靶点的重要步骤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cyclin-dependent-kinase inhibitors (CDKN)/retinoblastoma (RB1) pathway has been implicated as having a role in medullary thyroid carcinoma (MTC) tumorigenesis. CDKN2C loss has been associated with RET-mediated MTC in humans but with minimal phenotypic correlation provided. The objective of this study was to evaluate the association between tumor RET mutation status, CDKN2C loss, and aggressiveness of MTC in a cohort of patients with sporadic disease. METHODS: Tumors from patients with sporadic MTC treated at a single institution were evaluated for somatic RETM918T mutation and CDKN2C copy number loss. These variables were compared to patient demographics, pathology detail, clinical course, and disease-specific and overall survival. RESULTS: Sixty-two MTC cases with an initial surgery date ranging from 1983 to 2009 met the inclusion criteria, of whom 36 (58%) were male. The median age at initial surgery was 53 years (range 22-81 years). The median tumor size was 30 mm (range 6-145 mm) with 29 (57%) possessing extrathyroidal extension. Nodal and/or distant metastasis at presentation was found in 47/60 (78%) and 12/61 (20%) patients, respectively. Median follow-up time was 10.5 years (range 1.1-27.8 years) for the censored observations. The presence of CDKN2C loss was associated with worse M stage and overall AJCC stage. Median overall survival of patients with versus without CDKN2C loss was 4.14 [confidence interval (CI) 1.93-NA] versus 18.27 [CI 17.24-NA] years (p < 0.0001). Median overall survival of patients with a combined somatic RETM918T mutation and CDKN2C loss versus no somatic RETM918T mutation and CDKN2C loss versus somatic RETM918T mutation and CDKN2C 2N versus no somatic RETM918T mutation and CDKN2C 2N was 2.38 [CI 1.67-NA] years versus 10.81 [CI 2.46-NA] versus 17.24 [CI 9.82-NA] versus not reached [CI 13.46-NA] years (p < 0.0001). CONCLUSIONS: The detection of somatic CDKN2C loss is associated with the presence of distant metastasis at presentation as well decreased overall survival, a relationship enhanced by concomitant RETM918T mutation. Further defining the genes involved in the progression of metastatic MTC will be an important step toward identifying pathways of disease progression and new therapeutic targets.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Grubbs EG, Williams MD, Scheet P, et al. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma. Thyroid. 2016. PMID: 27610696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。